{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:32:31Z","timestamp":1793521951996,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,5]],"date-time":"2014-01-05T00:00:00Z","timestamp":1388880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s11899-013-0190-1","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T10:00:20Z","timestamp":1388829620000},"page":"17-23","source":"Crossref","is-referenced-by-count":30,"title":["Immunology and Immunotherapy of Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"9","author":[{"given":"Mette","family":"Ilander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Hekim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,5]]},"reference":[{"key":"190_CR1","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"190_CR2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200\u20136.","journal-title":"Leukemia"},{"key":"190_CR3","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540\u20136.","journal-title":"Blood"},{"key":"190_CR4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"190_CR5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"190_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"190_CR7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401\u201312.","journal-title":"Cancer Cell"},{"key":"190_CR8","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701\u20137.","journal-title":"Blood"},{"key":"190_CR9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319\u201325.","journal-title":"Blood"},{"key":"190_CR10","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","volume":"114","author":"RM Lemoli","year":"2009","unstructured":"Lemoli RM, Salvestrini V, Bianchi E, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood. 2009;114:5191\u2013200.","journal-title":"Blood"},{"key":"190_CR11","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109:4016\u20139.","journal-title":"Blood"},{"key":"190_CR12","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532\u20139.","journal-title":"Blood"},{"key":"190_CR13","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","year":"2013","unstructured":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439\u201342.","journal-title":"Blood"},{"key":"190_CR14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","volume":"26","author":"CI Chen","year":"2012","unstructured":"Chen CI, Koschmieder S, Kerstiens L, et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia. 2012;26:465\u201374.","journal-title":"Leukemia"},{"key":"190_CR15","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/eji.201142043","volume":"42","author":"A Rossignol","year":"2012","unstructured":"Rossignol A, Levescot A, Jacomet F, et al. Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. Eur J Immunol. 2012;42:1870\u20135.","journal-title":"Eur J Immunol"},{"key":"190_CR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2010.08453.x","volume":"153","author":"E Bachy","year":"2011","unstructured":"Bachy E, Bernaud J, Roy P, et al. Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. Br J Haematol. 2011;153:139\u201343.","journal-title":"Br J Haematol"},{"key":"190_CR17","doi-asserted-by":"crossref","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, Soderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One. 2013;8:e55818.","journal-title":"PLoS One"},{"key":"190_CR18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657\u201362.","journal-title":"Lancet"},{"key":"190_CR19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","volume":"103","author":"K Cathcart","year":"2004","unstructured":"Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103:1037\u201342.","journal-title":"Blood"},{"key":"190_CR20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2404354","volume":"20","author":"JH Kessler","year":"2006","unstructured":"Kessler JH, Bres-Vloemans SA, van Veelen PA, et al. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia. 2006;20:1738\u201350.","journal-title":"Leukemia"},{"key":"190_CR21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/107327480901600206","volume":"16","author":"J Pinilla-Ibarz","year":"2009","unstructured":"Pinilla-Ibarz J, Shah B, Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control. 2009;16:141\u201352.","journal-title":"Cancer Control"},{"key":"190_CR22","first-page":"1324","volume":"90","author":"J Pinilla-Ibarz","year":"2005","unstructured":"Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, et al. Synthetic peptide analogs derived from bcr\/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005;90:1324\u201332.","journal-title":"Haematologica"},{"key":"190_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","volume":"86","author":"JM Gerber","year":"2011","unstructured":"Gerber JM, Qin L, Kowalski J, et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol. 2011;86:31\u20137.","journal-title":"Am J Hematol"},{"key":"190_CR24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","volume":"111","author":"K Rezvani","year":"2008","unstructured":"Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236\u201342.","journal-title":"Blood"},{"key":"190_CR25","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541\u20138.","journal-title":"Blood"},{"key":"190_CR26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","volume":"116","author":"PG Maslak","year":"2010","unstructured":"Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116:171\u20139.","journal-title":"Blood"},{"key":"190_CR27","first-page":"176ra33","volume":"5","author":"T Dao","year":"2013","unstructured":"Dao T, Yan S, Veomett N, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013;5:176ra33. This study describes a human antibody targeting WT1, which is found in LSCs and solid tumors. The results are promising, but no studies have been done in humans yet.","journal-title":"Sci Transl Med"},{"key":"190_CR28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1658-3876(10)50053-0","volume":"3","author":"G Al Qudaihi","year":"2010","unstructured":"Al Qudaihi G, Lehe C, Dickinson A, et al. Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. Hematol Oncol Stem Cell Ther. 2010;3:24\u201333.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"190_CR29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0301-472X(02)00874-3","volume":"30","author":"J Greiner","year":"2002","unstructured":"Greiner J, Ringhoffer M, Taniguchi M, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol. 2002;30:1029\u201335.","journal-title":"Exp Hematol"},{"key":"190_CR30","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00262-011-1126-z","volume":"60","author":"M Smahel","year":"2011","unstructured":"Smahel M. Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol Immunother. 2011;60:1655\u201368.","journal-title":"Cancer Immunol Immunother"},{"key":"190_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-8722-4-21","volume":"4","author":"H Zheng","year":"2011","unstructured":"Zheng H, Chen Y, Chen S, et al. Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol. 2011;4:21.","journal-title":"J Hematol Oncol"},{"key":"190_CR32","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28:1429\u201335.","journal-title":"J Clin Oncol"},{"key":"190_CR33","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2003-07-2424","volume":"103","author":"H Fujiwara","year":"2004","unstructured":"Fujiwara H, El Ouriaghli F, Grube M, et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood. 2004;103:3076\u201383.","journal-title":"Blood"},{"key":"190_CR34","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","volume":"90","author":"JJ Molldrem","year":"1997","unstructured":"Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529\u201334.","journal-title":"Blood"},{"key":"190_CR35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood-2008-06-164889","volume":"113","author":"T Ochi","year":"2009","unstructured":"Ochi T, Fujiwara H, Suemori K, et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood. 2009;113:66\u201374.","journal-title":"Blood"},{"key":"190_CR36","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1158\/1078-0432.CCR-12-1182","volume":"18","author":"A Cai","year":"2012","unstructured":"Cai A, Keskin DB, DeLuca DS, et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012;18:5761\u201372.","journal-title":"Clin Cancer Res"},{"key":"190_CR37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med. 2013;19:465\u201372.","journal-title":"Nat Med"},{"key":"190_CR38","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Richter J, Barbany G, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 2013;27:1520\u20136.","journal-title":"Leukemia"},{"key":"190_CR39","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M Jaras","year":"2010","unstructured":"Jaras M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A. 2010;107:16280\u20135. This paper describes leukemia stem cell spesific expression of IL1RAP and its targeting with antibody therapy.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"190_CR40","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","volume":"121","author":"M Askmyr","year":"2013","unstructured":"Askmyr M, Agerstam H, Hansen N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709\u201313. The antibody treatment in this study specifically kills LSCs without affecting the normal HSCs and progenitor cells.","journal-title":"Blood"},{"key":"190_CR41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555\u201362.","journal-title":"Blood"},{"key":"190_CR42","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/mt.2012.227","volume":"21","author":"M Casucci","year":"2013","unstructured":"Casucci M, Perna SK, Falcone L, et al. Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene. Mol Ther. 2013;21:466\u201375.","journal-title":"Mol Ther"},{"key":"190_CR43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","volume":"94","author":"L Ruggeri","year":"1999","unstructured":"Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333\u20139.","journal-title":"Blood"},{"key":"190_CR44","doi-asserted-by":"crossref","first-page":"e27639","DOI":"10.1371\/journal.pone.0027639","volume":"6","author":"M Kijima","year":"2011","unstructured":"Kijima M, Gardiol N, Held W. Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo. PLoS One. 2011;6:e27639.","journal-title":"PLoS One"},{"key":"190_CR45","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","volume":"127","author":"J Salih","year":"2010","unstructured":"Salih J, Hilpert J, Placke T, et al. The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer. 2010;127:2119\u201328.","journal-title":"Int J Cancer"},{"key":"190_CR46","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","volume":"14","author":"R Weichsel","year":"2008","unstructured":"Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484\u201391.","journal-title":"Clin Cancer Res"},{"key":"190_CR47","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","volume":"111","author":"AE Schade","year":"2008","unstructured":"Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366\u201377.","journal-title":"Blood"},{"key":"190_CR48","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473\u20139.","journal-title":"Blood"},{"key":"190_CR49","first-page":"17","volume":"1","author":"A Kreutzman","year":"2013","unstructured":"Kreutzman A, Porkka K, Mustjoki S. Immunomodulatory Effects of Tyrosine Kinase Inhibitors. Int Trends Immun. 2013;1:17\u201328.","journal-title":"Int Trends Immun"},{"key":"190_CR50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:387\u201398.","journal-title":"Eur J Haematol."},{"key":"190_CR51","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","volume":"53","author":"Y Hayashi","year":"2012","unstructured":"Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma. 2012;53:1084\u20139.","journal-title":"Leuk Lymphoma"},{"key":"190_CR52","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"190_CR53","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V, et al. Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772\u201382.","journal-title":"Blood"},{"key":"190_CR54","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587\u201397.","journal-title":"Leukemia"},{"key":"190_CR55","doi-asserted-by":"crossref","first-page":"E916","DOI":"10.1002\/ijc.27537","volume":"131","author":"N Hassold","year":"2012","unstructured":"Hassold N, Seystahl K, Kempf K, et al. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer. 2012;131:E916\u201327.","journal-title":"Int J Cancer"},{"key":"190_CR56","doi-asserted-by":"crossref","unstructured":"Uchiyama T, Sato N, Narita M et al. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study. Hematol Oncol. 2012;31:156\u2013163","DOI":"10.1002\/hon.2034"},{"key":"190_CR57","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27:914\u201324. In this study rapid lymphocyte mobilization and transmigration induced by dasatinib therapy is described. No other TKIs were found to have similar effects.","journal-title":"Leukemia"},{"key":"190_CR58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12185-012-1132-8","volume":"96","author":"H Tanaka","year":"2012","unstructured":"Tanaka H, Nakashima S, Usuda M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int J Hematol. 2012;96:308\u201319.","journal-title":"Int J Hematol"},{"key":"190_CR59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","volume":"122","author":"H Lavallade de","year":"2013","unstructured":"de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227\u201338.","journal-title":"Blood"},{"key":"190_CR60","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/10428199509059647","volume":"18","author":"G Pawelec","year":"1995","unstructured":"Pawelec G, Da Silva P, Max H, et al. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma. 1995;18:471\u20138.","journal-title":"Leuk Lymphoma"},{"key":"190_CR61","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1080\/1042819031000110973","volume":"44","author":"FA Castro de","year":"2003","unstructured":"de Castro FA, Palma PV, Morais FR, et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma. 2003;44:2061\u20137.","journal-title":"Leuk Lymphoma"},{"key":"190_CR62","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511\u201321. Clinical study showing the beneficial effect of IFN-a in combination with TKI therapy.","journal-title":"N Engl J Med"},{"key":"190_CR63","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118:3228\u201335. Clinical study showing the beneficial effect of IFN-a in combination with TKI therapy.","journal-title":"Blood"},{"key":"190_CR64","doi-asserted-by":"crossref","unstructured":"Ilander M, Koskenvesa P, Hernesniemi S et al. Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy. Leuk Lymphoma. 2013. doi: 10.3109\/10428194.2013.812788","DOI":"10.3109\/10428194.2013.812788"},{"key":"190_CR65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","volume":"95","author":"H Itonaga","year":"2012","unstructured":"Itonaga H, Tsushima H, Hata T, et al. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol. 2012;95:209\u201313.","journal-title":"Int J Hematol"},{"issue":"Suppl 1","key":"190_CR66","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.clml.2011.03.032","volume":"11","author":"AM Cornelison","year":"2011","unstructured":"Cornelison AM, Welch MA, Koller C, Jabbour E. Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation. Clin Lymphoma Myeloma Leuk. 2011;11 Suppl 1:S111\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"190_CR67","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1\/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clin Cancer Res. 2013;19:5300\u20139.","journal-title":"Clin Cancer Res"},{"key":"190_CR68","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"190_CR69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333. Clinical study showing the beneficial effect of anti-PD1 antibody in combination with anti-CTLA4.","journal-title":"N Engl J Med"},{"key":"190_CR70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","volume":"26","author":"D Marin","year":"2012","unstructured":"Marin D, Gabriel IH, Ahmad S, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 2012;26:296\u2013302.","journal-title":"Leukemia"},{"key":"190_CR71","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2012-04-421016","volume":"120","author":"S Ali","year":"2012","unstructured":"Ali S, Sergeant R, O'Brien SG, et al. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood. 2012;120:697\u20138.","journal-title":"Blood"},{"key":"190_CR72","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","volume":"40","author":"A Kreutzman","year":"2012","unstructured":"Kreutzman A, Jaatinen T, Greco D, et al. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol. 2012;40:906\u201313 e1.","journal-title":"Exp Hematol"},{"key":"190_CR73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","volume":"41","author":"G Nasa La","year":"2013","unstructured":"La Nasa G, Caocci G, Littera R, et al. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol. 2013;41:424\u201331.","journal-title":"Exp Hematol"},{"key":"190_CR74","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"190_CR75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322. Results show that also patients who are successfully able to discontinue TKI therapy have BCR-ABL positive cells left when measured with sensitive DNA based assay.","journal-title":"Blood"},{"key":"190_CR76","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2141.2011.08939.x","volume":"157","author":"K Ohyashiki","year":"2012","unstructured":"Ohyashiki K, Katagiri S, Tauchi T, et al. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol. 2012;157:254\u20136.","journal-title":"Br J Haematol"},{"issue":"9","key":"190_CR77","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cas.12216","volume":"104","author":"I Mizoguchi","year":"2013","unstructured":"Mizoguchi I, Yoshimoto T, Katagiri S, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013;104(9):1146\u201353.","journal-title":"Cancer Sci"},{"key":"190_CR78","doi-asserted-by":"crossref","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","volume":"6","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One. 2011;6:e23022.","journal-title":"PLoS One"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-013-0190-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0190-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T11:02:41Z","timestamp":1597316561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-013-0190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,5]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["190"],"URL":"https:\/\/doi.org\/10.1007\/s11899-013-0190-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,5]]}}}